Borresen-Dale AL - Search Results

1

Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity.

Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, Gonzalez-Farre X, Muñoz M, Russnes HG, Helland A, Rye IH, Borresen-Dale AL, Maruyama R, van Oudenaarden A, Dowsett M, Jones RL, Reis-Filho J, Gascon P, Gönen M, Michor F, Polyak K. Almendro V, et al. Cell Rep. 2014 Feb 13;6(3):514-27. doi: 10.1016/j.celrep.2013.12.041. Epub 2014 Jan 23. Cell Rep. 2014. PMID: 24462293 Free PMC article.

2

Microsatellite instability in cervical and endometrial carcinomas.

Helland A, Børresen-Dale AL, Peltomäki P, Hektoen M, Kristensen GB, Nesland JM, de la Chapelle A, Lothe RA. Helland A, et al. Int J Cancer. 1997 Mar 4;70(5):499-501. doi: 10.1002/(sici)1097-0215(19970304)70:5<499::aid-ijc1>3.0.co;2-t. Int J Cancer. 1997. PMID: 9052745 Free article.

3

Absence of p21 expression is associated with abnormal p53 in human breast carcinomas.

Ellis PA, Lonning PE, Borresen-Dale A, Aas T, Geisler S, Akslen LA, Salter I, Smith IE, Dowsett M. Ellis PA, et al. Br J Cancer. 1997;76(4):480-5. doi: 10.1038/bjc.1997.413. Br J Cancer. 1997. PMID: 9275025 Free PMC article.

4

An increased risk of cervical intra-epithelial neoplasia grade II-III among human papillomavirus positive patients with the HLA-DQA1*0102-DQB1*0602 haplotype: a population-based case-control study of Norwegian women.

Helland A, Olsen AO, Gjøen K, Akselsen HE, Sauer T, Magnus P, Børresen-Dale AL, Rønningen KS. Helland A, et al. Int J Cancer. 1998 Mar 30;76(1):19-24. doi: 10.1002/(sici)1097-0215(19980330)76:1<19::aid-ijc4>3.0.co;2-0. Int J Cancer. 1998. PMID: 9533756 Free article.

5

Allelic imbalance at chromosome region 11q23 in cervical carcinomas.

Skomedal H, Helland A, Kristensen GB, Holm R, Børresen-Dale AL. Skomedal H, et al. Eur J Cancer. 1999 Apr;35(4):659-63. doi: 10.1016/s0959-8049(98)00413-4. Eur J Cancer. 1999. PMID: 10492643

6

p53 polymorphism and cervical cancer.

Helland A, Børresen-Dale AL. Helland A, et al. Lancet. 1999 Oct 30;354(9189):1561-2. doi: 10.1016/S0140-6736(05)76596-X. Lancet. 1999. PMID: 10551531 No abstract available.

7

Primary cervical carcinomas show 2 common regions of deletion at 3P, 1 within the FHIT gene: evaluation of allelic imbalance at FHIT, RB1 and TP53 in relation to survival.

Helland A, Kraggerud SM, Kristensen GB, Holm R, Abeler VM, Huebner K, Borresen-Dale AL, Lothe RA. Helland A, et al. Int J Cancer. 2000 Oct 15;88(2):217-22. doi: 10.1002/1097-0215(20001015)88:2<217::aid-ijc11>3.0.co;2-i. Int J Cancer. 2000. PMID: 11004671 Free article.

8

Fibroblast growth factor receptor 3 (FGFR3) - analyses of the S249C mutation and protein expression in primary cervical carcinomas.

Dai H, Holm R, Kristensen GB, Abeler VM, Børresen-Dale AL, Helland A. Dai H, et al. Anal Cell Pathol. 2001;23(2):45-9. doi: 10.1155/2001/521873. Anal Cell Pathol. 2001. PMID: 11904459 Free PMC article.

9

X chromosome inactivation in cervical cancer patients.

Kristiansen M, Helland A, Kristensen GB, Olsen AO, Lønning PE, Børresen-Dale AL, Ørstavik KH. Kristiansen M, et al. Cancer Genet Cytogenet. 2003 Oct 1;146(1):73-6. doi: 10.1016/s0165-4608(03)00152-3. Cancer Genet Cytogenet. 2003. PMID: 14499700

10

PIK3CA mutations in advanced ovarian carcinomas.

Wang Y, Helland A, Holm R, Kristensen GB, Børresen-Dale AL. Wang Y, et al. Hum Mutat. 2005 Mar;25(3):322. doi: 10.1002/humu.9316. Hum Mutat. 2005. PMID: 15712344

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

507 results

Search Page